Fig. 3.

PLX3397 effect on neurofibroma growth. a Experimental design, b Waterfall plots of tumor volume for control and PLX3397-treated Dhh-Cre; Nf1^flox/flox mice showed a subset of with decrease neurofibroma volume (negative values). Each bar shows data from a single mouse. The y axis shows neurofibroma tumor volume change from 7 to 9 months of age quantified by measurements of MRI scans, so that bars below the x axis indicate that tumors regressed over the treatment period. c Western blots showed that PLX3397 inhibited p-Kit and total Kit protein expression in Dhh-Cre; Nf1^flox/flox mouse neurofibromas at the end of treatment. β-actin serves as a loading control. d Quantification of numbers of toluidine blue-positive mast cells per high-powered field (hfp) (*p = 0.011). At least 10 fields were counted per section; averages from individual mice are shown as individual dots. e Tumor pharmacokinetics. Responding (Resp) and non-responding (NR) tumors contained >30 ng/PLX3397/g tissue. Dotted line shows efficacious concentration